Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study

Table 1 69 patients at study entry before treatment with Alirocumab or Evolocumab

Age at entry (years) Mean ± SD, [25th, 50th, 75th percentiles]	61.7 ± 9.4, [55, 64, 69]
BMI (kg/m²) Mean ± SD, [25th, 50th, 75th percentiles]	29.5 ± 4.8, [25.5, 29.0, 32.0]
Race	61 White (88%), 6 Black (9%), 1 Asian (1%), 1 Indian (1%)
Gender	36 F (52%), 33 M (48%)
Diabetes	9 Yes (13%), 60 No (87%)
Smoke	3 Yes (4%), 66 No (96%)
Antihypertensive drug	43 Yes (62%), 26 No (38%)
HeFH	44 Yes (64%), 25 No (36%); 25 had HeFH & no CVD (36%)
CVD	44 Yes (64%), 25 No (36%); 25 had CVD & no HeFH (36%)
Both HeFH & CVD	19 (28%)
Statin intolerant	46 Yes (67%), 23 No (33%)
Medication use at entry Taking Statin (n = 23)	Statin only, N = 13
	Statin + ezetimibe, N = 3
	Statin + colesevelam, N = 1
	Statin + ezetimibe + colesevelam, N = 6
Not taking statin (n = 46)	Ezetimibe only, N = 2
	Colesevelam only, N = 2
	Ezetimibe + colesevelam, N = 3
	Nothing, N = 39
Follow up weeks Mean ± SD, [25th, 50th, 75th %tiles] on ALI 75 mg Q2W (n = 29)	49 ± 13, [38, 49, 59]
on ALI 150 mg (n = 18) or EVO 140 mg (n = 22) Q2W, data pooled	37 ± 12 [26, 33, 45]
Total cohort (n = 69)	42 ± 14 [30, 40, 51]

ISSN: 1476-511X